Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Dec 31, 2025
Reporting period
Not applicable
Filed with the SEC
Jan 5, 2026
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001225208-26-000163
Filed / recorded
Jan 5, 2026, 9:38 PM UTC
Added to OQRO
Oct 1, 2026, 11:17 PM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
PFIZER INC
Issuer CIK
78003
Ticker
PFE
Reporting person
Albert Bourla
Relationship
Director, Officer
Officer title
Chairman & CEO
Security
Phantom Stock Units SSP
Table
Derivative (Table II)
Transaction date
Dec 31, 2025
Transaction code
A
Shares / units
24
Price per share
$24.90
Acquired / disposed
Acquired (A)
Shares owned after
743,147
Ownership form
Direct
Amendment
No
Footnotes from the filing
Each unit represents one phantom share of common stock.
These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
The Department of Defense placed a delivery order with Pfizer for naloxone vials, committing $2.8K so far. This order was made under an existing larger agreement and was open to any bidder, making it a routine purchase.
The Department of Defense placed a delivery order for $9,048 of naloxone vials from Pfizer on January 26, 2026. This order was made under an existing agreement and was open to any bidder, making it a routine purchase rather than a unique or unusual transaction.
